Literature DB >> 9952380

Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy.

M P Karavellas1, D J Plummer, J C Macdonald, F J Torriani, C L Shufelt, S P Azen, W R Freeman.   

Abstract

This study was conducted to determine the likelihood of the development of a new ocular inflammatory syndrome (immune recovery vitritis, IRV), which causes vision loss in AIDS patients with cytomegalovirus (CMV) retinitis, who respond to highly active antiretroviral therapy (HAART). We followed 30 HAART-responders with CD4 cell counts of >/=60 cells/mm3. Patients were diagnosed with IRV if they developed symptomatic vitritis of >/=1+ severity associated with inactive CMV retinitis. Symptomatic IRV developed in 19 (63%) of 30 patients and in 26 (59%) of 44 eyes over a median follow-up from HAART response of 13.5 months. The annual incidence of IRV was 83/100 person-years. Excluding patients with previous cidofovir therapy did not significantly alter the time course of IRV (P=.79). These data suggest that IRV develops in a significant number of HAART-responders with CMV retinitis and is unrelated to previous cidofovir therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9952380     DOI: 10.1086/314639

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

1.  [Immune reconstitution syndrome].

Authors:  D Meyer-Olson; D Ernst; M Stoll
Journal:  Z Rheumatol       Date:  2012-04       Impact factor: 1.372

2.  Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture.

Authors:  Douglas A Jabs
Journal:  Am J Ophthalmol       Date:  2010-12-18       Impact factor: 5.258

3.  Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomes.

Authors:  Douglas A Jabs; Alka Ahuja; Mark Van Natta; Alice Lyon; Sunil Srivastava; Sapna Gangaputra
Journal:  Ophthalmology       Date:  2010-07-29       Impact factor: 12.079

4.  Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy.

Authors:  J P Casazza; M R Betts; L J Picker; R A Koup
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Therapy and Prevention of Cytomegalovirus Retinitis.

Authors:  Asok Kurup; Francesca J. Torriani
Journal:  Curr Infect Dis Rep       Date:  2001-08       Impact factor: 3.725

6.  Cytomegalovirus Retinitis in Patients With Acquired Immunodeficiency Syndrome After Initiating Antiretroviral Therapy.

Authors:  Douglas A Jabs; Mark L Van Natta; Gary N Holland; Ronald Danis
Journal:  Am J Ophthalmol       Date:  2016-10-27       Impact factor: 5.258

7.  The prevalence and incidence of epiretinal membranes in eyes with inactive extramacular CMV retinitis.

Authors:  Igor Kozak; Vijay Vaidya; Mark L Van Natta; Jeong W Pak; K Patrick May; Jennifer E Thorne
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-06-12       Impact factor: 4.799

8.  Canadian consensus guidelines for the management of cytomegalovirus disease in HIV/AIDS.

Authors:  Richard G Lalonde; Guy Boivin; Jean Deschênes; William G Hodge; J Jill Hopkins; Alex H Klein; Janette I Lindley; Peter Phillips; Stephen D Shafran; Sharon Walmsley
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-11       Impact factor: 2.471

9.  Optimal management of cytomegalovirus retinitis in patients with AIDS.

Authors:  Michael W Stewart
Journal:  Clin Ophthalmol       Date:  2010-04-26

10.  Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001.

Authors:  I Yust; Z Fox; M Burke; A Johnson; D Turner; A Mocroft; C Katlama; B Ledergerber; P Reiss; O Kirk
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-06-30       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.